Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Scientists Eradicate Leukemic Stem Cells by Targeting Cell Survival Proteins

Posted on: 27 Oct 16

SCIEX, a global leader in life science analytical technologies, today announced an exciting application leveraging SCIEX LC-MS instruments and chemistries. An interdisciplinary research team led by Professor Tessa Holyoake from the University of Glasgow and Professor Tony Whetton from the University of Manchester, UK, has uncovered two proteins that are important to the survival of chronic myeloid leukemia (CML) stem cells. The team used this finding to design a new targeted treatment for CML, demonstrating that dual targeting of the transcription factors p53 and c-MYC can eradicate leukemic stem cells (LSCs). The study was recently published in Nature1 and exemplifies a novel precision medicine approach to advance leukemia research.

Currently, Tyrosine Kinase Inhibitors (TKIs) are used as the standard CML treatment, which has substantially improved patient outcomes over previous therapies. However, these drugs do not kill the LSCs that maintain the disease, so TKIs must be taken continuously by the patient, resulting in ever-increasing costs to sustain remissions. This pressing need to develop curative therapies versus ongoing treatments drove the team to apply a systems biology approach to identify key protein networks that perpetuate the CML phenotype.

Using a systems biology approach, combining both transcriptomic and proteomic analyses, was essential to identify those proteins and corresponding regulators which have a defining role in CML LSC survival. Amongst the SCIEX solutions utilized in this study are the SCIEX TripleTOF® 5600+ System which provides both comprehensive qualitative exploration and high-resolution quantitation on a single platform. iTRAQ® reagents are also used in the study, which are novel labeling chemistries specifically designed for simplifying complex protein expression analysis, enabling researchers to identify key peptides with high sensitivity and selectivity. The scientists found a network of 30 proteins that are central to survival of CML cells and regulated by the p53 and c-MYC transcription factors. The study also demonstrated the novel potential therapeutic advantage of selectively targeting these two transcription factors, which highlights the importance of precision medicine approaches, to provide the right drug, to the right patient, at the right time.

“This collaborative study combined proteomics, transcriptomics and systems biology to identify a novel precision medicine-based approach for eradicating leukemic stem cells,” states Professor Whetton. “It is another example of the power that precision medicine holds for the future of treatments, cures for disease and healthcare advancements at large.”

Professor Tony Whetton is also Director of the recently opened Stoller Biomarker Discovery Centre at the University of Manchester. The multi-million pound Centre focuses on biomedical research including cancer, psoriasis and arthritis, using mass spectrometry-based proteomics solutions from SCIEX. View online Stoller Biomarker Discovery Centre Opening Symposium, which includes leading researcher video presentations.

“At SCIEX, our mission is to enable powerful scientific insights that deliver life-changing answers,” states Jean-Paul Mangeolle, President of SCIEX. “This work is an excellent example of how our MS-based proteomics solutions enable our customers to make important discoveries for the future of precision medicine.”

Learn more about SCIEX’s life science research solutions utilized by customers in the advancement of precision medicine.

View the abstract or the Nature article (subscription required): Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells


1. Abraham, S.A., Hopcroft, L.E.M., Carrick, E., Drotar, M.E., Dunn, K., Williamson, A.J.K., Korfi, K., Baquero, P., Park, L.E., Scott, M.T., Pellicano, F., Pierce, A., Copland, M., Nourse, C., Grimmond, S.M., Vetrie, D., Whetton, A.D. and Holyoake, T.L. (2016) ‘Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells’, Nature, 534 (7607): pp. 341–346.


SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry Industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit

SCIEX social: Twitter: @SCIEXnews,LinkedIn and Facebook.

For research use only. Not for use in diagnostic procedures. RUO-MKT-12-4509-A

AB Sciex is operating as SCIEX.

© 2016 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.

View source version on

Business Wire

Last updated on: 27/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.